These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 29505186)

  • 21. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up.
    Pittenger C; Kelmendi B; Wasylink S; Bloch MH; Coric V
    J Clin Psychopharmacol; 2008 Jun; 28(3):363-7. PubMed ID: 18480706
    [No Abstract]   [Full Text] [Related]  

  • 22. The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.
    Moskal JR; Burgdorf JS; Stanton PK; Kroes RA; Disterhoft JF; Burch RM; Khan MA
    Curr Neuropharmacol; 2017; 15(1):47-56. PubMed ID: 26997507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketamine successfully terminates malignant status epilepticus.
    Prüss H; Holtkamp M
    Epilepsy Res; 2008 Dec; 82(2-3):219-22. PubMed ID: 18804344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of riluzole augmentation in a patient with treatment-resistant obsessive-compulsive disorder, taking two other glutaminergic agents.
    Mahgoub N; Asemota B; Alexopoulos GS
    J Neuropsychiatry Clin Neurosci; 2011; 23(2):E24-5. PubMed ID: 21677213
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of ketamine.
    Stahl SM
    CNS Spectr; 2013 Aug; 18(4):171-4. PubMed ID: 23866089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Riluzole Serum Concentration in Pediatric Patients Treated for Obsessive-Compulsive Disorder.
    Grant P; Farmer C; Song J; Kish T; Swedo S
    J Clin Psychopharmacol; 2017 Dec; 37(6):713-716. PubMed ID: 29045303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder.
    Grant P; Song JY; Swedo SE
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):309-15. PubMed ID: 20807069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ketamine on precipitated opiate withdrawal.
    Jovaisa T; Laurinenas G; Vosylius S; Sipylaite J; Badaras R; Ivaskevicius J
    Medicina (Kaunas); 2006; 42(8):625-34. PubMed ID: 16963828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.
    Adams TG; Bloch MH; Pittenger C
    J Clin Psychopharmacol; 2017 Apr; 37(2):269-271. PubMed ID: 28121735
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report.
    Uzun O
    J Psychopharmacol; 2010 Mar; 24(3):425-7. PubMed ID: 19010977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged exposure to ketamine increases brain derived neurotrophic factor levels in developing rat brains.
    Ibla JC; Hayashi H; Bajic D; Soriano SG
    Curr Drug Saf; 2009 Jan; 4(1):11-6. PubMed ID: 19149520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex.
    Zhou W; Wang N; Yang C; Li XM; Zhou ZQ; Yang JJ
    Eur Psychiatry; 2014 Sep; 29(7):419-23. PubMed ID: 24321772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Repeated Ketamine Infusion Over Facial Emotion Recognition in Treatment-Resistant Depression: A Preliminary Report.
    Shiroma PR; Albott CS; Johns B; Thuras P; Wels J; Lim KO
    J Neuropsychiatry Clin Neurosci; 2015; 27(4):362-4. PubMed ID: 25658683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning-Based Treatment Outcome in Obsessive-Compulsive Disorder: A Pilot Study.
    Linkovski O; Wheaton MG; Zwerling J; Odgerel Z; van Roessel P; Filippou-Frye M; Lombardi A; Wright B; Steinman SA; Simpson HB; Lee F; Rodriguez CI
    J Clin Psychopharmacol; 2019; 39(1):91-93. PubMed ID: 30531475
    [No Abstract]   [Full Text] [Related]  

  • 38. Ketamine as an antidepresessant: a brief research history.
    Wanderer JP; Rathmell JP
    Anesthesiology; 2014 Jul; 121(1):A29. PubMed ID: 24936933
    [No Abstract]   [Full Text] [Related]  

  • 39. Cytokine, chemokine and BDNF levels in medication-free pediatric patients with obsessive-compulsive disorder.
    Çolak Sivri R; Bilgiç A; Kılınç İ
    Eur Child Adolesc Psychiatry; 2018 Aug; 27(8):977-984. PubMed ID: 29302747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous clomipramine for obsessive-compulsive disorder.
    Koran LM; Faravelli C; Pallanti S
    J Clin Psychopharmacol; 1994 Jun; 14(3):216-8. PubMed ID: 8027426
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.